Posted by Michael Wonder on 18 May 2017
GlycoMimetics' GMI-1271 receives FDA breakthrough therapy designation for adult relapsed/refractory acute myeloid leukaemia
17 May 2017 - GlycoMimetics today announced that the U.S. FDA has granted breakthrough therapy designation for treatment of adult relapsed/refractory acute myeloid leukaemia to the company's drug candidate GMI-1271, an E-selectin antagonist currently being evaluated in the Phase 2 portion of a Phase 1/2 clinical trial in patients with acute myeloid leukaemia.
The U.S. FDA had previously granted orphan drug designation and fast track status for GMI-1271 in acute myeloid leukaemia.
